Following extensive progress in the treatment of relapsing multiple sclerosis, the major challenge in the field is now to develop effective therapies for progressive forms of multiple sclerosis. As the first signs of success emerge, now is the time to consider the research needed to move the field forward.
This is a preview of subscription content, log in via an institution to check access.
References
Lublin, F. D. et al. The 2013 clinical course descriptors for multiple sclerosis: a clarification. Neurology 94, 1088–1092 (2020).
Brownlee, W. J. et al. Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis. Brain 142, 2276–2287 (2019).
Eshaghi, A. et al. Progression of regional grey matter atrophy in multiple sclerosis. Brain 141, 1665–1677 (2020).
Martinez-Lapiscina, E. H. et al. Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study. Lancet Neurol. 15, 574–584 (2016).
Kapoor, R. et al. Serum neurofilament light as a biomarker in progressive multiple sclerosis. Neurology https://doi.org/10.1212/WNL.0000000000010346 (2020).
Chataway, J. et al. Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial. Lancet Neurol. 19, 214–225 (2020).
Absinta, M., Lassmann, H. & Trapp, B. D. Mechanisms underlying progression in multiple sclerosis. Curr. Opin. Neurol. 33, 277–285 (2020).
Neumann, B. et al. Problems and pitfalls of identifying remyelination in Multiple Sclerosis. Cell Stem Cell 26, 617–619 (2020).
Wheeler, M. A. et al. MAFG-driven astrocytes promote CNS inflammation. Nature 578, 593–599 (2020).
Feinstein, A. et al. CogEx Research Team. Study protocol: improving cognition in people with progressive multiple sclerosis: a multi-arm, randomized, blinded, sham-controlled trial of cognitive rehabilitation and aerobic exercise (COGEx). BMC Neurol. 20, 204 (2020).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
A.J.T. has served on scientific advisory boards and received honoraria from Eisai and Abbvie; has received support for travel from the International Progressive Multiple Sclerosis Alliance as chair of their Scientific Steering Committee, and from the National Multiple Sclerosis Society as a member of their Research Programs Advisory Committee; receives an honorarium from SAGE Publishers as Editor-in-Chief of Multiple Sclerosis Journal; is an editorial board member for Lancet Neurology; and receives research support from NIHR and the NIHR UCLH Biomedical Research Centre. O.C. has served on scientific advisory boards and has received honoraria and support for travel from Merck, Novartis and Roche; is Deputy Editor for Neurology; serves on the editorial board for Multiple Sclerosis Journal; receives research support from EPSRC, MS Society of GB and NI, National MS Society, NIHR, the NIHR UCLH/UCL Biomedical Research Centre and the Rosetrees Trust.
Rights and permissions
About this article
Cite this article
Thompson, A., Ciccarelli, O. Towards treating progressive multiple sclerosis. Nat Rev Neurol 16, 589–590 (2020). https://doi.org/10.1038/s41582-020-00421-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41582-020-00421-4
- Springer Nature Limited
This article is cited by
-
PD-L1 positive astrocytes attenuate inflammatory functions of PD-1 positive microglia in models of autoimmune neuroinflammation
Nature Communications (2023)
-
Choroid plexus-selective inactivation of adenosine A2A receptors protects against T cell infiltration and experimental autoimmune encephalomyelitis
Journal of Neuroinflammation (2022)
-
The role of glial cells in multiple sclerosis disease progression
Nature Reviews Neurology (2022)
-
Positron emission tomography in multiple sclerosis — straight to the target
Nature Reviews Neurology (2021)
-
Neurology at the crossroads
Nature Reviews Neurology (2020)